Evidence map›Paper›PMID 42469878›Full record

ArticleChinese medicine2026

Co-production of high-purity floridoside and isofloridoside ameliorates MASH via Parabacteroides goldsteinii-UDCA-FXR enterohepatic axis.

Shuang Li, Rong Guo, Linxiao Sun, Peng Zhu, Tingting Wang, JianJun Zheng, Haimin Chen, Hongshan Li

Abstract read
In one paragraph

Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuang LiNingbo No.2 Hospital, Wenzhou Medical University, Ningbo, 315000, China.
Rong GuoHangzhou Medical College, Hangzhou, 310053, Zhejiang, China.
Linxiao SunCollaborative Innovation Center for Zhejiang Marine High‑Efficiency and Healthy Aquaculture, Ningbo University, Ningbo, 315211, Zhejiang, China.
Peng ZhuNingbo No.2 Hospital, Wenzhou Medical University, Ningbo, 315000, China.
Tingting WangCollaborative Innovation Center for Zhejiang Marine High‑Efficiency and Healthy Aquaculture, Ningbo University, Ningbo, 315211, Zhejiang, China.
JianJun ZhengNingbo No.2 Hospital, Wenzhou Medical University, Ningbo, 315000, China. lishuang23@ucas.ac.cn.
Haimin ChenCollaborative Innovation Center for Zhejiang Marine High‑Efficiency and Healthy Aquaculture, Ningbo University, Ningbo, 315211, Zhejiang, China. chenhaimin@nbu.edu.cn.
Hongshan LiNingbo No.2 Hospital, Wenzhou Medical University, Ningbo, 315000, China. lihongshan1982@126.com.

Funding

National Natural Science Foundation of China No.32373099Ningbo Natural Science Foundation No.2024J422Ningbo Top Medical and Health Research Program No.2024020919
6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatohepatitis (MASH), the progressive form of metabolic dysfunction-associated fatty liver disease (MAFLD), is tightly linked to gut microbiota dysbiosis and disrupted bile acid (BA) homeostasis. Floridoside (Flor), a marine glycoside from the edible seaweed Pyropia haitanensis (P. haitanensis), exerts promising biological activities. However, protocols for its high-purity preparation and the mechanisms underlying its anti-MASH effects remain unclear. PURPOSE: To develop a protocol for the preparation of high-purity Flor and its isomer isofloridoside (Isoflor) from P. haitanensis, and to elucidate how Flor alleviates MASH via regulating gut microbiota and BA metabolism.

methodsHigh-purity Flor and Isoflor were isolated via integrated chromatography, with their chemical structures confirmed by LC-MS and NMR. Anti-MASH efficacy was evaluated in a high-fat diet (HFD)-induced murine MASH model. The underlying mechanisms were explored using multi-omics analyses, including transcriptomics, gut microbiota metagenomics and BA-targeted metabolomics, and further validated by molecular docking, molecular dynamics simulation and western blotting; the compounds' biosafety was evaluated using zebrafish.

resultsHigh-purity Flor and Isoflor were successfully isolated, each with a purity of ≥ 99.0%. Both compounds exhibited a favorable biosafety profile and comparable lipid-lowering activity in zebrafish. In HFD-induced murine MASH models, Flor robustly ameliorated HFD-driven obesity, hepatic steatosis, and chronic inflammation, and restored systemic BA homeostasis characterized by a markedly increased non-12-OH/12-OH BA ratio. Meanwhile, Flor treatment dramatically enriched the relative abundance of intestinal Parabacteroides goldsteinii (P. goldsteinii), which showed a significant positive correlation with MASH alleviation and beneficial BAs (e.g., ursodeoxycholic acid (UDCA)). Mechanistically, UDCA exerted its therapeutic effects by antagonizing FXR signaling, upregulating the hepatic protein and mRNA expression of CYP7B1 and CYP27A1, and ultimately promoting the activation of the alternative BA synthesis pathway.

conclusionHigh-purity Flor and Isoflor were obtained via an integrated co-production process from P. haitanensis. We hypothesize that Flor may ameliorate MASH by enriching P. goldsteinii and modulating the UDCA-FXR axis to activate the alternative bile acid synthesis pathway, positioning Flor as a promising prebiotic candidate for MASH management.

Indexed as

Alternative bile acid synthesis pathwayCo-production of Floridoside and IsofloridosideGut-liver axisMetabolic dysfunction-associated steatohepatitisParabacteroides goldsteiniiPyropia haitanensis

Identifiers

PMID42469878
PMCPMC13377823

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.